Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Gene therapy in dogs shows hope for muscular dystrophy
Labrador
In the study, dogs - which have a similar body size to that of a diseased boy - were injected with the disease when they were two to three months old.

Researchers on the cusp of having a treatment for the disease

A team of researchers have successfully treated dogs with muscular dystrophy using gene therapy. The treatment could pave the the way for clinical trials in humans within the next few years.

The study, published in the journal Human Molecular Genetics, demonstrates for the first time that a common virus can deliver the microgene, which protects against the virus, to all muscles in that of diseased dog.

Muscular dystrophy affects around 250,000 people in the USA and occurs when damaged muscle tissue is replaced with fibrous, fatty or bony tissue and loses function.

Patients with the disease have a gene mutation that disrupts the production of a protein known as 'dystrophin". This is one of the largest genes in the human body and its absence can eventually lead to muscle cell degeneration and death.

Study leader Dongsheg Duan from the University of Missouri explains: “Due to its size, it is impossible to deliver the entire gene with a gene therapy vector, which is the vehicle that carries the therapeutic gene to the correct site in the body.

“Through previous research, we were able to develop a miniature version of this gene called a microgene. This minimised dystrophin protected all muscles in the body of diseased mice.”

In the study, dogs - which have a similar body size to that of a diseased boy - were injected with the disease when they were two to three months old and just starting to show signs of muscular dystrophy.  The dogs are now six to seven months old and continue to develop normally.

“The virus we are using is one of the most common viruses; it is also a virus that produces no symptoms in the human body, making this a safe way to spread the dystrophin gene throughout the body,” added Duan.

“These dogs develop muscular dystrophy naturally in a similar manner as humans. It’s important to treat DMD early before the disease does a lot of damage as this therapy has the greatest impact at the early stages in life.”

Margaret Proctor Mulligan from the University of Missouri's School of Medicine said: “This discovery took our research team more than 10 years, but we believe we are on the cusp of having a treatment for the disease.”

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.